A Study of BLEX 404 Oral Liquid in Patients With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML)
This is a clinical trial to determine the safety, recommended dose level (RDL), and infection control of BLEX 404 Oral Liquid in combination with azacitidine in patients with International Prognostic Scoring System (IPSS) intermediate-1 (int-1), intermediate-2 (int-2) or high-risk myelodysplastic syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML).
Myelodysplastic Syndrome (MDS)
DRUG: BLEX 404 Oral Liquid
Part I: Recommended dose level (RDL) of BLEX 404 Oral Liquid, RDL is defined by BLEX 404 Oral Liquid-related prohibited toxicity in subjects undergoing 2 cycles of azacitidine treatment. When one of the stopping criteria is met during the study treatment period, RDL will be set at the lower dose level., 8 weeks (2 cycles of azacitidine)|Part II: Incidence of infections, Number of subjects experience infection events and inpatient hospitalization due to infections., 24 weeks (6 cycles of azacitidine)
Part I: (A) Number of subjects experience infections events and inpatient hospitalization due to infections, 8 weeks (2 cycles of azacitidine)|Part I: (B) Treatments and duration of each infections, 8 weeks (2 cycles of azacitidine)|Part I: (C) Complete remission (CR) or partial remission (PR) of bone marrow, peripheral blood, cytogenetic response (defined by 2006 IWG Criteria), Hematological Response in subjects undergone BLEX 404 Oral Liquid in combination with 2 cycles of azacitidine., 8 weeks (2 cycles of azacitidine)|Part I: (D) Hematological improvement of erythroid (hemoglobin and RBC-transfusion independence), neutrophil (Absolute Neutrophil Count), and platelet (platelet count) response (defined by 2006 IWG Criteria), Hematological Response in subjects undergone BLEX 404 Oral Liquid in combination with 2 cycles of azacitidine., 8 weeks (2 cycles of azacitidine)|Part I: (E) Frequency and requirement of red blood cell transfusion (defined by 2006 IWG Criteria), Hematological Response in subjects undergone BLEX 404 Oral Liquid in combination with 2 cycles of azacitidine., 8 weeks (2 cycles of azacitidine)|Part I: (F) Disease Progression (defined by 2006 IWG Criteria), Disease progression of bone marrow, erythroid (hemoglobin and RBC-transfusion independence), and platelet (platelet count) in subjects undergone BLEX 404 Oral Liquid treatment in combination with 2 cycles of azacitidine., 8 weeks (2 cycles of azacitidine)|Part II: (A) Time-to-first infection, 24 weeks (6 cycles of azacitidine)|Part II: (B) Duration (days) of each infection event, 24 weeks (6 cycles of azacitidine)|Part II: (C) Number of infections requiring supportive care or antimicrobial agents, 24 weeks (6 cycles of azacitidine)|Part II: (D) Duration (days) of treatments for infections, 24 weeks (6 cycles of azacitidine)|Part II: (E) Complete remission (CR) or partial remission (PR) of bone marrow, peripheral blood, cytogenetic response (defined by 2006 IWG Criteria), Hematological Response in subjects undergone BLEX 404 Oral Liquid in combination with 6 cycles of azacitidine., 24 weeks (6 cycles of azacitidine)|Part II: (F) Hematological improvement of erythroid (hemoglobin and RBC-transfusion independence), neutrophil (Absolute Neutrophil Count), and platelet (platelet count) response (defined by 2006 IWG Criteria), Hematological Response in subjects undergone BLEX 404 Oral Liquid in combination with 6 cycles of azacitidine., 24 weeks (6 cycles of azacitidine)|Part II: (G) Frequency and requirement of red blood cell transfusion (defined by 2006 IWG Criteria), Hematological Response in subjects undergone BLEX 404 Oral Liquid in combination with 6 cycles of azacitidine., 24 weeks (6 cycles of azacitidine)|Part II: (H) Disease Progression (defined by 2006 IWG Criteria), Disease progression of bone marrow, erythroid (hemoglobin and RBC-transfusion independence), and platelet (platelet count) in subjects undergone BLEX 404 Oral Liquid treatment in combination with 2 cycles of azacitidine., 24 weeks (6 cycles of azacitidine)|Part II: (I) Six-month overall survival rate (defined by 2006 IWG Criteria), defined as time from beginning of treatment till death from any cause occurs or last follow-up., 24 weeks (6 cycles of azacitidine)|Part II: (J) Six-month progression-free survival (defined by 2006 IWG Criteria), defined as time from beginning of treatment till disease progression, death from MDS or CMML, or last follow-up., 24 weeks (6 cycles of azacitidine)|Part II: (K) Immune Response, Neutrophil and monocyte function by respiratory burst assay, 24 weeks (6 cycles of azacitidine)
This is a clinical trial to determine the safety, recommended dose level (RDL), and infection control of BLEX 404 Oral Liquid in combination with azacitidine in patients with International Prognostic Scoring System (IPSS) intermediate-1 (int-1), intermediate-2 (int-2) or high-risk myelodysplastic syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML).